SWOG clinical trial number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Open
Phase
Abbreviated Title
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Status Notes
This study is active in SWOG as of July 1, 2020.
Activated
07/01/2020

Research committees

Gastrointestinal Cancer

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2023

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer

A Chawla;Q Shi;A Ko;M Beg;A Varghese;M Noel;M Bloomston;F Ahmed;W Frankel;J Dixon;X Carrero;A Shergill;J Crawley;O Akin;D Renouf;G Zogopoulos;J Hubbard;J Meyerhardt;E O'Reilly;C Ferrone J Clin Oncol 41, 2023 (suppl 16; abstr TPS4204); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
73%
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
27%
Open
Phase